Assignee
SIGNALRX PHARMACEUTICALS INC
US·9 granted patents·2 pending applications·37 citations·filing 2013–2023
Top patents by PatentIndex Score
11 records- 0193US9505780B2Thienopyranones as kinase and epigenetic inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2015·Granted Nov 29, 2016·9 cites·2 claims
- 0291US10308662B2Thienopyranones as kinase and epigenetic inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2017·Granted Jun 4, 2019·6 cites·11 claims
- 0389US9981983B2Thienopyranones as kinase inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2016·Granted May 29, 2018·5 cites·4 claims
- 0489US9550790B2Thienopyranones as kinase inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2013·Granted Jan 24, 2017·8 cites·1 claims
- 0588US10174032B2Heterocyclic compound classes for signaling modulationSIGNALRX PHARMACEUTICALS INC·Filed 2015·Granted Jan 8, 2019·6 cites·2 claims
- 0679US11472814B2Thienopyranones and furanopyranones as checkpoint inhibitors and modulators of anti-tumor immunitySIGNALRX PHARMACEUTICALS INC·Filed 2018·Granted Oct 18, 2022·3 cites·18 claims
- 0774US12577254B2Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2023·Granted Mar 17, 2026·0 cites·6 claims
- 0858US2017101418A1Thienopyranones as Kinase and Epigenetic InhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0957US11760762B2Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2018·Granted Sep 19, 2023·0 cites·6 claims
- 1054US2023165873A1Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19SIGNALRX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1144US12570668B2Single molecule compounds providing multi-target inhibition of BTK and other proteins and methods of use thereofSIGNALRX PHARMACEUTICALS INC·Filed 2019·Granted Mar 10, 2026·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when SIGNALRX PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →